Back to Search
Start Over
Amiodarone-associated Optic Neuropathy: A Critical Review
- Source :
- The American Journal of Medicine. 125:447-453
- Publication Year :
- 2012
- Publisher :
- Elsevier BV, 2012.
-
Abstract
- Although amiodarone is the most commonly prescribed anti-arrhythmic drug, its use is limited by serious toxicities, including optic neuropathy. Current reports of amiodarone-associated optic neuropathy identified from the Food and Drug Administration's Adverse Event Reporting System and published case reports were reviewed. A total of 296 reports were identified: 214 from the Adverse Event Reporting System, 59 from published case reports, and 23 from adverse events reports for patients enrolled in clinical trials. Mean duration of amiodarone therapy before vision loss was 9 months (range 1-84 months). Insidious onset of amiodarone-associated optic neuropathy (44%) was the most common presentation, and nearly one third were asymptomatic. Optic disk edema was present in 85% of cases. Following drug cessation, 58% had improved visual acuity, 21% were unchanged, and 21% had further decreased visual acuity. Legal blindness (
- Subjects :
- Pediatrics
medicine.medical_specialty
Visual acuity
genetic structures
Amiodarone
Blindness
Asymptomatic
Article
Optic neuropathy
Adverse Event Reporting System
Optic Nerve Diseases
medicine
Humans
Adverse effect
business.industry
General Medicine
medicine.disease
eye diseases
Clinical trial
Anesthesia
Decreased Visual Acuity
medicine.symptom
business
Anti-Arrhythmia Agents
medicine.drug
Subjects
Details
- ISSN :
- 00029343
- Volume :
- 125
- Database :
- OpenAIRE
- Journal :
- The American Journal of Medicine
- Accession number :
- edsair.doi.dedup.....f75e73227f952fe6994635bb2d97220e